Commentary

Podcast

Dr Lucio Gordan Discusses Updated Guidelines Addressing 1q Abnormalities in Multiple Myeloma

Author(s):

Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute, discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.

In this edition of Managed Care Cast, Executive Editor Mary Caffrey speaks with Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists & Research Institute. Gordan discusses recently updated clinical guidelines from the National Comprehensive Cancer Network (NCCN) in multiple myeloma, which specifically discuss disease staging and risk stratification and advise clinicians on how to address 1q abnormalities.

Review the NCCN guideline update discussed in this podcast.

The guidelines follow the Second revision of the International Staging System (R2-ISS), which appeared in the December 2022 issue of the Journal of Clinical Oncology, the official publication of the American Society of Clinical Oncology.1

Listen above or on one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify

Reference

  1. D'Agostino M, Cairns DA, Lahuerta JJ, et al. Second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the Harmony project. J Clin Oncol 2022;40(29):3406-3418. doi:10.1200/JCO.21.02614
Related Videos
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS)
Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute
Gustavo Fonseca, MD, FACP, Florida Cancer Specialists & Research Institute
Jennifer Gass, PhD, FACMG, associate director, Genetics Laboratory, Florida Cancer Specialists & Research Institute
Eneline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA
Nathan Walcker, CEO of Florida Cancer Specialists.
Nate Walcker, CEO of Florida Cancer Specialists.
Nathan H. Walcker, MBA.
Michael Diaz, MD.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo